Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

The enzyme Dgat1 is essential for healthy hair and skin by controlling retinoid levels.

The combination therapy was effective and well-tolerated, especially in young patients.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

New treatment for hair loss using special microneedles shows promise in reducing inflammation and promoting hair growth.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Direct-to-consumer teledermatology effectively treats male hair loss but may increase drug costs and requires monitoring for side effects.

Dextroamphetamine may help treat alopecia areata.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

A new type of sudden, complete female hair loss was found, with most patients fully recovering within 6 months without needing steroid treatment.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.

AMT is the best surfactant for hair and scalp care.

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

H+-ATPase is crucial for plant growth and can be influenced by microbial compounds, affecting root hair development.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Tiger tail banding and hair abnormalities are reliable indicators for diagnosing trichothiodystrophy.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.